Market Size of Primary Biliary Cholangitis (PBC) Therapeutics Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 10.00 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players_Therapeutics_COmpanies.webp "Primary Biliary Cholangitis (PBC) Therapeutics Market Major Players")
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Primary Biliary Cholangitis Market Analysis
The global primary biliary cholangitis (PBC) market is projected to grow with a CAGR of nearly 10% over the forecast period. The growth is attributed to the increase in cases of primary biliary cholangitis and increasing R&D investment in the development of new therapeutics for the disease. Due to the recurring nature of the disease currently, there are only a few treatment options available for the disease, primarily liver transplantation. Moreover, regenerative and stem cell therapies are at the nascent stage which will drive the market growth of therapeutics over the forecast period. However, the asymptomatic nature of the disease delays diagnosis and treatment, lack of awareness among the population about the disease and stringent regulatory policies are the factors that are anticipated to hamper the market growth.
Primary Biliary Cholangitis Industry Segmentation
Primary biliary cholangitis also known as primary biliary cirrhosis is an autoimmune disease of the liver. This results from the slow and progressive destruction of the biliary cells. Currently, a limited number of therapeutics are approved for the treatment of primary biliary cholangitis.
| By Drug | |
| Obeticholic Acid | |
| Ursodeoxycholic Acid | |
| Others |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Primary Biliary Cholangitis (PBC) Therapeutics Market Size Summary
The global primary biliary cholangitis (PBC) therapeutics market is experiencing significant growth, driven by an increase in the incidence of the disease and heightened research and development investments aimed at creating new treatment options. Currently, treatment options are limited, primarily to liver transplantation, due to the disease's recurring nature. The market is also witnessing interest in regenerative and stem cell therapies, although these are still in the early stages of development. Despite these advancements, challenges such as the asymptomatic nature of PBC, lack of public awareness, and stringent regulatory policies pose obstacles to market expansion. Existing therapeutics like Ocaliva and Ursodeoxycholic acid are used to manage the disease, with Ocaliva being a primary drug despite recent regulatory warnings affecting its usage.
Regionally, North America is expected to see substantial market growth, supported by a robust healthcare infrastructure, the presence of key industry players, and recent product launches. The increasing number of PBC cases and the rising demand for therapeutics are further propelling market growth in this region. The competitive landscape of the global PBC therapeutics market is moderately intense, with major players such as Intercept Pharmaceuticals, Teva Pharmaceutical, Allergan Inc., and Glenmark Pharmaceuticals focusing on new product developments, innovations, and expanding their geographical reach. The ongoing need for new therapeutics development is a key focus for market participants, which is anticipated to drive further growth in the coming years.
Primary Biliary Cholangitis (PBC) Therapeutics Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing R&D For Development of New Drug Therapeutics For Primary Biliary Cholangitis
-
1.2.2 Growing Burden of Primary Biliary Cholangitis and Liver Related Disorders
-
-
1.3 Market Restraints
-
1.3.1 Stringent Regulatory Policies
-
1.3.2 Lack of Awareness Regarding Liver Disorders
-
-
1.4 Porter's Five Force Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 By Drug
-
2.1.1 Obeticholic Acid
-
2.1.2 Ursodeoxycholic Acid
-
2.1.3 Others
-
-
2.2 Geography
-
2.2.1 North America
-
2.2.1.1 United States
-
2.2.1.2 Canada
-
2.2.1.3 Mexico
-
-
2.2.2 Europe
-
2.2.2.1 Germany
-
2.2.2.2 United Kingdom
-
2.2.2.3 France
-
2.2.2.4 Italy
-
2.2.2.5 Spain
-
2.2.2.6 Rest of Europe
-
-
2.2.3 Asia-Pacific
-
2.2.3.1 China
-
2.2.3.2 Japan
-
2.2.3.3 India
-
2.2.3.4 Australia
-
2.2.3.5 South Korea
-
2.2.3.6 Rest of Asia-Pacific
-
-
2.2.4 Middle-East and Africa
-
2.2.4.1 GCC
-
2.2.4.2 South Africa
-
2.2.4.3 Rest of Middle-East and Africa
-
-
2.2.5 South America
-
2.2.5.1 Brazil
-
2.2.5.2 Argentina
-
2.2.5.3 Rest of South America
-
-
-
Primary Biliary Cholangitis (PBC) Therapeutics Market Size FAQs
What is the current Primary Biliary Cholangitis (PBC) Therapeutics Market size?
The Primary Biliary Cholangitis (PBC) Therapeutics Market is projected to register a CAGR of 10% during the forecast period (2024-2029)
Who are the key players in Primary Biliary Cholangitis (PBC) Therapeutics Market?
Intercept Pharmaceuticals, Inc., Teva Pharmaceutical, Mylan Inc., Allergan Inc. and Glenmark Pharmaceuticals are the major companies operating in the Primary Biliary Cholangitis (PBC) Therapeutics Market.
